Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...

The global diabetes injection pens market is projected to grow at a CAGR of approximately 7% through 2028. Market expansion ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...

This image showcases two creative dessert preparation concepts using bright rainbow colors. On the left, smooth rainbow cake ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

About SHINE Technologies, LLC Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

She's in bed waiting, and you can't track down where on your body that smell is coming from. Make sure you're clean for her ...

Former Florida State Prison Warden Ron McAndrew argues that Florida's rapid scheduling of executions is pushing the state's ...

An oral formulation of semaglutide has received United States Food and Drug Administration approval for a new drug or biologic under the Prescription Drug User Fee Act. The University of Alabama at ...

In a new brief report, researchers caution against repeating past mistakes in HIV prevention, as high drug prices and insurance coverage issues have slowed uptake of long-acting, bimonthly injectable ...